MAPK13 and lung carcinoma: These results suggest that FOS, HMOX1, ABCG2, NFE2L2, KLF4, and MAPK13, which have been reported to be associated with therapy-induced survival signaling (Figure 4G), are the main regulators of chemoresistance in PC9GR cells and thereby could be a promising signature to promote chemosensitivity by MNL4924 treatment in lung cancer.